Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 579

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 579
---
 | ​ 
 ​ | Year Ended December 31,     
 2023                        |   |       |   |   |   |          |   |     |   | ​ | ​ | 2022 |   |       |   |   |   |          |   |      |   | ​ 
 ​ |
|:------------------|:--|:--|:----------------------------|:--|------:|:--|:--|:--|:---------|:--|:----|:--|:--|:--|:-----|:--|------:|:--|:--|:--|:---------|:--|:-----|:--|:--|
| ​                 | ​ | ​ | Dollar amounts in thousands |   |       |   |   |   |          |   |     |   |   |   |      |   |       |   |   |   |          |   |      |   | ​ |
| ​                 | ​ | ​ | ​                           | ​ |     ​ | ​ | ​ | ​ | % change |   |     |   | ​ | ​ | ​    | ​ |     ​ | ​ | ​ | ​ | % change |   |      |   | ​ |
| Other income, net | ​ | ​ | ​                           | $ | 3,586 | ​ | ​ | ​ | ​        | ​ | 74% | ​ | ​ | ​ | ​    | $ | 2,061 | ​ | ​ | ​ | ​        | ​ | 221% | ​ | ​ |

For the year ended December 31, 2023 compared to the year ended December 31, 2022, the increase in other income, net was primarily due to an increase in interest income resulting from a higher yield on our portfolio of investments during the year ended December 31, 2023 and an increase in accretion income from our available-for-sale marketable securities. We reviewed our available-for-sale debt securities as of December 31, 2023 and 2022 and determined that no credit loss expense was necessary as a result of unrealized losses on various securities not being considered material individually or in aggregate, and we expect that the cost basis of these available-for-sale securities is recoverable. We do not expect that unrealized losses on our available-for-sale debt securities will impact our liquidity in the short-term or long-term since our investments all mature at various dates through November